Latest Entitlement Offer News

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

My Rewards International Limited reports a 47% revenue drop but narrows losses by 45%, fueled by strategic acquisition and tech innovation. The company advances ASX reinstatement with a capital raise and debt conversion plan.

Cyprium Metals Limited has launched an A$80 million capital raise to fast-track the restart of its Nifty Copper Complex, aiming to unlock significant value from its brownfield assets. The funds will support refurbishment, feasibility studies, and strengthen the company’s balance sheet.

Cardiex Limited’s FY2025 results reveal a sharp 67% revenue decline driven by the prior year’s one-off clinical trial payment, while net losses nearly doubled despite ongoing cost reduction efforts and significant capital raises.

MEC Resources Ltd has reported a net profit of $207,490 for the 2025 financial year, reversing prior losses, while advancing a significant legal challenge through its investee Advent Energy Ltd and raising $2.6 million via an entitlement offer.

I Synergy Group Limited reported a 21.5% revenue decline to A$378,627 and an 80.8% reduction in losses for the half-year ended June 2025, while securing over A$1 million in capital and signing a strategic AI technology supply deal.

DTI Group Ltd reported an 11% revenue increase and secured a $4 million Adelaide Metro contract, alongside a $2.69 million capital raise to fuel growth. The company also deepened global partnerships and enhanced its technology platform during FY25.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

Carbonxt Group Limited reported a 7.1% revenue increase and a significant EBITDA improvement in FY25, while commissioning delays at its Kentucky facility temper near-term optimism.

Carbonxt Group Limited reported a 7.1% revenue increase to $16.2 million in FY25 alongside a 16.7% reduction in net loss, while progressing its Kentucky liquid-phase activated carbon facility and navigating ongoing liquidity challenges.

Xamble Group Limited reported a sharp 39% revenue decline and a doubling of losses in H1 FY2025, driven by strategic exit from Taiwan and increased technology spending. Despite financial setbacks, operational metrics show strong user and client growth, underpinning the company’s Southeast Asia-focused transformation.